natgillin/translations-raw huggingface dataset:
Alle infliximab b 
All infliximab b
Hvis en patient ikke viser respons efter 14 uger (det vil sige efter 4 doser), bør der ikke gives yderligere behandling med Flixabi. 
If a patient shows no response after 14 weeks (i.e. after 4 doses), no additional treatment with Flixabi should be given.
Cyanose, perikardieeffusion. 
Cyanosis, pericardial effusion.
Kredsløbssvigt, petekkier, vasospasme. 
Circulatory failure, petechia, vasospasm.
Patienter i gruppe 2, som havde en BASDAI ≥ 3 ved 2 på hinanden følgende konsultationer, fik 7,5 mg/kg infliximab hver 6. uge startende med uge 36 og frem til uge 96. 
In Group 2, starting with the week 36 infusion, patients who had a BASDAI ≥ 3 at 2 consecutive visits, received 7.5 mg/kg infliximab every 6 weeks thereafter through week 96.
Infliximab med eller uden AZA blev vurderet i et randomiseret, dobbeltblind studie med aktiv komparator (SONIC) hos 508 voksne patienter med moderat til svær Crohns sygdom (CDAI ≥ 220 ≤ 
Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study (SONIC) of 508 adult patients with moderate to severe Crohn's disease (CDAI ≥ 220 ≤ 450) who were naive to biologics and immunosuppressants and had a median disease duration of 2.3 years.
Infliximabs sikkerhed og virkning hos børn under 6 år med colitis ulcerosa er ikke undersøgt. 
The safety and efficacy of infliximab have not been studied in children with ulcerative colitis below the age of 6 years.
I tilfælde heraf må lægemidlet ikke sættes tilbage på køl. 
In this situation, do not return to refrigerated storage again.
Almindelig: Vertigo, svimmelhed, hypæstesi, paræstesi. 
Vertigo, dizziness, hypoaesthesia, paraesthesia.
• Infektioner i skeden. 
• Infections of the vagina.
Der er set pancytopeni, leukopeni, neutropeni og trombocytopeni hos patienter, der fik TNF- hæmmere, herunder infliximab. 
There have been reports of pancytopenia, leucopenia, neutropenia, and thrombocytopenia in patients receiving TNF-blockers, including infliximab.
• Fortæl din læge, hvis du har eller nogensinde har haft en lidelse, som påvirker dit nervesystem, 
• Tell your doctor if you have or have ever had a problem that affects your nervous system before you are given Flixabi.
Efter infliximab- behandling udviste patienter nedsat niveau af serum interleukin 6 (IL-6) og C-reaktiv protein (CRP). 
After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline.
• Disse infektioner kan være alvorlige og indbefatter tuberkulose, infektioner forårsaget af virus, svampe, bakterier eller andre organismer i miljøet samt blodforgiftning, som kan være livstruende. 
• These infections may be serious and include tuberculosis, infections caused by viruses, fungi,
Bivirkninger 
IMPACT
Flixabi er indiceret til behandling af moderat til svær, aktiv colitis ulcerosa hos voksne patienter, som har haft utilstrækkelig respons af konventionel behandling inklusive kortikosteroider og 6-mercaptopurin (6-MP) eller azathioprin (AZA), eller som er intolerante over for eller har kliniske kontraindikationer for sådanne behandlinger. 
Flixabi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Flixabi er indiceret til behandling af svær, aktiv Crohns sygdom hos børn og unge mellem 6 og 17 år, som ikke har responderet på konventionel behandling inklusive kortikosteroid, immunmodulator og primær ernæringsbehandling, eller som er intolerante over for eller hvor der er kontraindikationer mod sådanne behandlinger. 
Flixabi is indicated for treatment of severe, active Crohn's disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
• Medicinenvil blive givet som en infusion (drop) (over 2 timer) i en af dine blodårer (vener), 
• The medicine will be given as an infusion (drip) (over 2 hours) into one of your veins, usually in your arm. After the third treatment, your doctor may decide to give your dose of Flixabi over 1 hour.
Hos patienter med positiv test for HBV-infektion, anbefales det at rådføre sig med en læge med erfaring i behandling af hepatitis B. Bærere af HBV, hvor behandling med Flixabi er nødvendig, skal følges nøje under behandlingen og i adskillige måneder efter afslutning af behandlingen for at registrere tegn og symptomer på aktiv HBV-infektion. 
Carriers of HBV who require treatment with Flixabi should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Urinvejsinfektion. 
Urinary tract infection.
Det anbefales, at pædiatriske patienter bliver vaccineret i overensstemmelse med gældende vaccinationsvejledninger, før Flixabi-behandling påbegyndes, hvis dette er muligt. 
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Flixabi therapy.
Uge 54 Fistula respons (%)a 
Complete fistula response (%)
Lungeødem, bronkospasme, pleuritis, pleural effusion. 
Pulmonary oedema, bronchospasm, pleurisy, pleural effusion.
Hvis du er i tvivl, om noget af ovenstående passer på dig, skal du kontakte lægen, før du får Flixabi. 
If you are not sure if any of the above applies to you, talk to your doctor before you are given Flixabi.
Nedre luftvejsinfektion (fx bronchitis, pneumoni), dyspnø, næseblod. 
Lower respiratory tract infection (e.g. bronchitis, pneumonia), dyspnoea, epistaxis.
HÆTTEGLAS-ETIKET 
VIAL LABEL
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs hjemmeside.http://www.ema.europa.eu. 
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Brug af anden medicin sammen med Flixabi 
Other medicines and Flixabi
Flixabi 100 mg pulver til koncentrat, opløsning infliximab 
Flixabi 100 mg powder for concentrate infliximab
Psoriasis hos voksne Effekten af infliximab blev vurderet i to multicenter, randomiserede, dobbeltblinde studier: SPIRIT og 
The efficacy of infliximab was assessed in two multicentre, randomised, double-blind studies: SPIRIT and EXPRESS.
I kliniske studier har forsinkede overfølsomhedsreaktioner været usædvanlige og er forekommet efter infliximab-fri perioder på mindre end 1 år (se pkt. 
In clinical studies, delayed hypersensitivity reactions have been uncommon and have occurred after infliximab-free intervals of less than 1 year (see sections 4.4 and 4.8).
Denne medicin indeholder mindre end 1 mmol (23 mg) natrium pr. dosis, dvs. den er i det væsentlige natriumfri. 
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodiumfree'.However, before Flixabi is given to you, it is mixed with a solution that contains sodium.
Tarmperforation, tarmstenose, diverticulitis, pancreatitis, keilitis. 
Intestinal perforation, intestinal stenosis, diverticulitis, pancreatitis, cheilitis.
Flixabi er indiceret til behandling af svær, aktiv colitis ulcerosa hos børn og unge i alderen 6 til 17 år, som har responderet utilstrækkeligt på konventionel behandling, inklusive kortikosteroider og 6-MP eller AZA, eller som er intolerante over for eller hvor der er kontraindikationer mod disse behandlinger. 
Flixabi is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies.
Der kan opstå svimmelhed under behandling med Flixabi (se pkt. 
Dizziness may occur following administration of Flixabi (see section 4.8).
Levende vacciner bør ikke gives samtidig med Flixabi. 
It is recommended that live vaccines not be given concurrently with Flixabi.
• eller alene hos patienter, der udviser intolerance over for methotrexat, eller for hvem methotrexat er kontraindiceret 
Flixabi should be administered  in combination with methotrexate  or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.
Vaskulære sygdomme Almindelig: 
Hepatobiliary disorders Common:
Infliximabs effekt og sikkerhed blev undersøgt i to multicenter, dobbeltblinde, placebokontrollerede studier hos patienter med aktiv ankyloserende spondylitis (Bath Ankylosing Spondylitis Disease 
Efficacy and safety of infliximab were assessed in two multicentre, double-blind, placebo-controlled studies in patients with active ankylosing spondylitis (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score ≥ 4 and spinal pain ≥ 4 on a scale of 1-10).
Tegn inkluderer feber, træthedsfølelse, (vedvarende) hoste, åndenød, vægttab, natlig svedtendens, diarré, sår, tandproblemer, en brændende smerte, når du lader vandet, eller influenzalignende symptomer. 
Signs include a fever, feeling tired, (persistent) cough, shortness of breath, weight loss, night sweats, diarrhea, wounds, dental problems, burning when urinating or ‘flulike' signs.
Flixabi 100 mg pulver til koncentrat til infusionsvæske, opløsning infliximab 
Flixabi 100 mg powder for concentrate for solution for infusion infliximab
Hvis en patient ikke responderer efter 3 doser, bør der ikke gives yderligere behandling med Flixabi. 
If a patient does not respond after 3 doses, no additional treatment with Flixabi should be given.
Leversvigt. 
Headache.
Der bør ikke indgives levende vacciner (fx BCG-vaccine) til spædbørn, eksponeret for infliximab i uterus, i mindst 6 måneder efter fødslen (se pkt. 
Administration of live vaccines (e.g. BCG vaccine) to infants exposed to infliximab in utero is not recommended for at least 6 months after birth (see sections 4.4 and 4.5).
Median tid til tab af respons efter uge 54 
Median time to loss of response through
Pyelonefritis. 
Pyelonephritis.
Brystsmerte, træthed, feber, reaktioner på injektionsstedet, kulderystelser, ødem. 
Chest pain, fatigue, fever, injection site reaction, chills, oedema.
Flixabi, i kombination med methotrexat, er indiceret til reduktion af sygdomstegn og symptomer samt forbedring af fysisk funktionsevne hos: 
Flixabi, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:  adult patients with active disease when the response to disease-modifying antirheumatic drugs
Forringet heling. 
Impaired healing.
Flixabi 100 mg pulver til koncentrat til infusionsvæske, opløsning. 
Flixabi 100 mg powder for concentrate for solution for infusion.
Hvis en patient ikke responderer ved uge 6 (det vil sige efter 2 doser), bør der ikke gives yderligere behandling med Flixabi. 
If a patient does not respond by 6 weeks (i.e. after 2 doses), no additional treatment with Flixabi should be given.
De patienter, der fik kortikosteroider ved baseline, fik ikke kortikosteroider i de 3 måneder forud for uge 54. 
b CDAI < 150 at both week 30 and 54 and not receiving corticosteroids in the 3 months prior to week 54 among patients who were receiving corticosteroids at baseline.
4.4 og 4.8 for mere information omkring sikkerhed ved brug af infliximab hos ældre patienter. 
For more information about the safety of infliximab in elderly patients (see sections 4.4 and 4.8).
Hos børn og unge kan endvidere ses følgende bivirkninger: 
Additional side effects in children and adolescents
Følgende bivirkninger forekom hyppigere hos børn: nedsat antal røde blodlegemer (anæmi), blod i afføringen, nedsat samlet indhold af hvide blodlegemer (leukopeni), anfaldsvis ansigtsrødme, 
The side effects that happened more in children were: low red blood cells (anaemia), blood in stool, low overall levels of white blood cells (leucopenia), redness or blushing (flushing), viral infections, low levels of white blood cells that fight infection (neutropenia), bone fracture, bacterial infection and allergic reactions of the breathing tract.
Tabel 1 Bivirkninger i kliniske studier og efter markedsføring Infektioner og parasitære sygdomme Meget almindelig: Virusinfektion (fx influenza, herpes virus infektioner). 
Table 1 Undesirable effects in clinical studies and from post-marketing experience Infections and infestations Very Common:
• behandling af moderat til svært aktiv Crohns sygdom hos voksne patienter, som ikke har responderet på trods af en fuldstændig og adækvat behandling med et kortikosteroid og/eller et immunsuppressivum, eller som er intolerante over for eller har kliniske kontraindikationer for sådanne behandlinger. 
Adult Crohn's disease Flixabi is indicated for:  treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
≤ 3 års sygdomsvarighed, median 0,6 år) aktiv reumatoid arthritis (median antallet af hævede og ømme led var henholdsvis 19 og 31). 
The ASPIRE study evaluated responses at 54 weeks in 1,004 methotrexate naive patients with early (≤ 3 years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender joint count of 19 and 31, respectively).
• Fornyet indgift: Doser på 5 mg/kg, hvis sygdomstegn og symptomer på sygdommen kommer igen, efterfulgt af infusionsdoser på 5 mg/kg hver 8. uge (se "Fornyet indgift" nedenfor samt pkt. 
In responding patients, the alternative strategies for continued treatment are:  Maintenance: Additional infusions of 5 mg/kg every 8 weeks or  Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur followed by infusions of 5 mg/kg every 8 weeks (see ‘Re-administration' below and section 4.4).
Terapeutiske smitstoffer bør ikke gives samtidig med Flixabi. 
It is recommended that therapeutic infectious agents not be given concurrently with Flixabi.
Vedvarende respons (klinisk respons både i uge 8 og uge 30)a 
Sustained response (clinical response at both week
Det drejede sig om 4 ud af 22 (18,2 %) i 8-ugers vedligeholdelsesbehandlingsgruppen og 3 ud af 23 (13,0 %) i 12-ugers vedligeholdelsesbehandlingsgruppen. 
Overall, 8 (13.3%) of 60 treated patients experienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8 week and 3 of 23 (13.0%) in the q12 week treatment maintenance group.
Hvert Flixabi-hætteglas indeholder 100 mg infliximab. 
Each Flixabi vial contains 100 mg infliximab.
Fortæl straks din læge, hvis du får tegn på TB under behandlingen med Flixabi. 
Tell your doctor straight away if you get signs of TB during treatment with Flixabi.
Et hætteglas indeholder 100 mg infliximab*. 
One vial contains 100 mg of infliximab*.
Der er ikke tilgængelige data om antiviral behandling profylaktisk mod HBV-reaktivering i forbindelse med TNF-antagonist-behandling hos patienter, som er bærere af HBV. Flixabi bør seponeres hos patienter, hvor HBV reaktiveres, og effektiv antiviral behandling med passende understøttende behandling bør igangsættes. 
In patients who develop HBV reactivation, Flixabi should be stopped and effective antiviral therapy with appropriate supportive treatment should be initiated.
Psykiske forstyrrelser Almindelig: 
Nervous system disorders Very common:
Kortvarigt synstab under infusionen eller inden for 2 timer efter infusionen. 
Transient visual loss occurring during or within 2 hours of infusion.
DANMARK 
DENMARK
Fortæl straks din læge, hvis du får tegn på infektion under behandling med Flixabi. 
Tell your doctor straight away if you get signs of infection during treatment with Flixabi.
• Kulderystelser, hævelse på grund af ophobning af væske under huden 
• Chills, a build up of fluid under the skin causing swelling
Infliximabs sikkerhed og virkning blev vurderet i et multicenter, randomiseret, open-label, parallelgruppe klinisk studie (C0168T72) hos 60 pædiatriske patienter i alderen 6 til 17 år (medianalder 
The safety and efficacy of infliximab were assessed in a multicentre, randomised, open-label, parallel-group clinical study (C0168T72) in 60 paediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; endoscopic subscore ≥ 2) with an inadequate response to conventional therapies.
Fornyet indgift ved ankyloserende spondylitis Sikkerhed og virkning ved fornyet indgift, udover hver 6. til 8. uge, er ikke klarlagt (se pkt. 
The safety and efficacy of re-administration, other than every 6 to 8 weeks, has not been established (see sections 4.4 and 4.8).
Fortæl det straks til lægen, hvis du får symptomer på lave blodtal under behandlingen med Flixabi. 
Tell your doctor straight away if you get symptoms of low blood counts during treatment with Flixabi.
Efter rekonstitution indeholder hver ml 10 mg infliximab. 
After reconstitution, each ml contains 10 mg of infliximab.
Efter klargøring indeholder hver ml 10 mg infliximab. 
After preparation each mL contains 10 mg of infliximab.
Terapeutiske smitstoffer bør ikke gives samtidig med Flixabi (se pkt. 
It is recommended that therapeutic infectious agents not be given concurrently with Flixabi (see section 4.4).
Lever- og galdevejshændelser I kliniske studier er let til moderate stigninger i ALAT og ASAT set hos patienter, der fik infliximab, 
In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients receiving infliximab without progression to severe hepatic injury.
Det er vigtigt, at du fortæller dit barns læger og andet sundhedspersonale, at du har fået Flixabi, før barnet bliver vaccineret (for mere information, se afsnit om vaccination). 
• It is important that you tell your baby's doctors and other healthcare professionals about your Flixabi use before your baby is given any vaccine.
Slimhindeheling i uge 30a a p < 0,001 for hver infliximab-behandlingsgruppe mod placebo. 
a a p < 0.001, for each infliximab treatment group vs. placebo
Fortæl straks din læge, hvis du får symptomer på en nervesygdom under behandlingen med Flixabi. 
Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Flixabi.
Gennemsnit ± SDa 
Mean ± SD
Så meget Flixabi vil du få 
How much Flixabi is given
Efter rekonstitution indeholder 1 ml 10 mg infliximab. 
After reconstitution one mL contains 10 mg infliximab.
Gennemsnit ± SDd a p < 0,001, for hver infliximab-behandlingsgruppe mod kontrol. 
Mean ± SDd a p < 0.001, for each infliximab treatment group vs control b greater values indicate more joint damage.
Hvis patienten ikke responderer efter 2 doser, bør der ikke behandles yderligere med Flixabi. 
If a patient does not respond after 2 doses, no additional treatment with Flixabi should be given.
Icepharma hf Sími: + 354 800 9836 
Sími: + 354 800 9836
• voksne patienter med aktiv sygdom, når responset til sygdomsmodulerende antireumatiske lægemidler (DMARDs), inklusive methotrexat, har været utilstrækkeligt. 
(DMARDs), including methotrexate, has been inadequate.
Fortæl det straks til lægen, hvis du får symptomer på lupus under behandlingen med Flixabi. 
Tell your doctor straight away if you develop symptoms of lupus during treatment with Flixabi.
** PASI 75 respons for IMPACT ikke inkluderet som følge af lav N; p < 0,001 for infliximab vs. placebo i uge 24 for IMPACT 2. 
* ITT-analysis where subjects with missing data were included as non-responders a Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who entered the open-label extension b Based on patients with PASI ≥ 2.5 at baseline for IMPACT, and patients with ≥ 3% BSA psoriasis skin involvement at baseline in IMPACT 2 ** PASI 75 response for IMPACT not included due to low N; p < 0.001 for infliximab vs. placebo at week 24 for IMPACT 2
Almindelig: kan forekomme hos op til 1 ud af 10 personer 
Common: may affect up to 1 10 people
I det andet kliniske studie (IMPACT 2) blev effekt og sikkerhed af infliximab undersøgt hos 200 
In the second clinical study (IMPACT 2), efficacy and safety of infliximab were studied in 200 patients with active psoriatic arthritis (≥ 5 swollen joints and ≥ 5 tender joints).
Luftveje, thorax og mediastinum Meget almindelig: Øvre luftvejsinfektion, sinuitis. 
Respiratory, thoracic and mediastinal disorders Very common:
• Leversvigt 
(furunculosis)
Før behandlingen med Flixabi påbegyndes, skal patienten testes for HBV-infektion. 
Patients should be tested for HBV infection before initiating treatment with Flixabi.
Du må ikke få Flixabi og Kineret samtidig. 
Flixabi and Kineret should not be used together.
Brug ikke Flixabi 
AZA Monotherapy
Fortæl det straks til lægen, hvis du får symptomer på leverproblemer under behandlingen med Flixabi. 
Tell your doctor straight away if you get symptoms of liver problems during treatment with Flixabi.
Patientinformationskortet skal udleveres til patienter, som er i behandling med Flixabi. 
Patients treated with Flixabi should be given the patient reminder card.
Ikke almindelig: kan forekomme hos op til 1 ud af 100 personas 
Uncommon: may affect up to1 in 100 people
Mave-tarm-kanalen 
Olof Palmestraat 10
Keratitis, periorbitalt ødem, bygkorn. 
Keratitis, periorbital oedema, hordeolum.
Flixabi bør administreres 
How Flixabi is given
drænet ved forsigtigt tryk, ved mindst to på hinanden følgende besøg (med 4 ugers mellemrum) uden øget brug af lægemidler eller kirurgisk indgreb for Crohns sygdom. 
The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in the use of medicinal products or surgery for Crohn's disease.
HAQ ændring fra baseline over tiden e 
HAQ change from baseline over timee (patients evaluated) Mean ± SD
Fornyet indgift ved psoriasis arthritis Sikkerhed og virkning ved fornyet indgift, udover hver 8. uge, er ikke klarlagt (se pkt. 
The safety and efficacy of re-administration, other than every 8 weeks, has not been established (see sections 4.4 and 4.8).
Kontrol a 3 mg/kg hver 8. uge 
3 mg/kg q 8 wks
(van der Heijdemodified Sharp score) Ændring fra baseline (Gennemsnit ± SD 
Patients with ACR20 response/ Patients evaluated (%) Total scored (van der Heijde-modified Sharp score) Change from baseline (Mean ± SD
Procent forsøgspersoner med slimhindeheling Slimhindeheling i uge 8a 
Percentage of subjects with mucosal healing Mucosal healing at week 8
Flixabi. 
Apathy.
Sådan skal du bruge Flixabi 
How to store Flixabi
Opbevaring 
Indication
(hepatosplenisk T-celle- lymfom) 
(anaphylactic shock)
Ydermere er der efter markedsføring blevet rapporteret tilfælde af hepatosplenisk T-celle- lymfom hos patienter i behandling med infliximab. 
Post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with TNFblocking agents including infliximab.
Artralgi, myalgi, rygsmerter. 
Arthralgia, myalgia, back pain.
Hos patienter, som fik infliximab, er langt de fleste tilfælde forekommet hos patienter med Crohns sygdom eller colitis ulcerosa, og de fleste blev rapporteret hos unge og unge voksne mænd. 
In addition, post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with infliximab with the vast majority of cases occurring in Crohn's disease and ulcerative colitis, and most of whom were adolescent or young adult males (see section 4.4).
Instruktion i anvendelse og håndtering - rekonstitution, fortynding og administration 
Instructions for use and handling - reconstitution, dilution and administration In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered medicinal product should be clearly recorded.
5 mg/kg (i uge 24) 
5 mg/kg